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Multiple sclerosis and other myelin diseases affect the quality of life many people. In the 
United States alone, multiple sclerosis afflicts as many as 400,000 individuals.  Myelin, 
which is attacked by multiple sclerosis, plays a critical role in maintaining the healthy 
function of the adult nervous system.  There are many model systems that study myelin 
and its formation and loss. Our lab investigates the cuprizone model of demyelination and 
remyelination.  The cuprizone model is commonly believed only to affect adult 
oligodendrocytes, which it kills.  The current study investigates whether other cells in the 
oligodendrocyte line, such as oligodendrocyte progenitor cells, might also be susceptible to 
xii 
the toxic effects of cuprizone.  Oligodendrocyte progenitor cells may play an important 
role in repairing and replacing myelin after demyelinating insults. So any effect that the 
model has on these cells may be relevant to the use of the model for studying 
remyelination. In order to evaluate the potential effects of cuprizone, dividing cells in adult 
mice were labeled with the proliferation marker, Bromodeoxyuridine (BrdU).  
Immunohistochemical labeling of BrdU shows that the number of actively dividing cells 
seen in the subventricular and subgranular zones sharply and dramatically decreases after 
just 1 week on cuprizone.  In the following weeks, the number of dividing cells increases, 
but even after 3 weeks of recovery without cuprizone, the number of BrdU+ cells does not 
return to control levels. These results may have significant ramifications in the 
interpretation of results obtained from the cuprizone model, and this finding must be 
considered in selecting a model for future demyelination studies. 
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The Significance and Modeling of Demyelination and Remyelination 
 
 
 
 
The role of the nervous system can be simplified to sending, receiving, and integrating 
signals.  As these functions do not necessarily occur in the same place in the nervous system 
or even in the same parts of a given cell, the successful and reliable conduction of signals 
from one place to another is of critical importance to the function of the entire nervous 
system.  In many cases, the conduction of action potentials (APs) is critically dependent on 
the presence of a healthy sheath of myelin enveloping the axon.  The myelin sheaths along an 
axon enable the high transmission speeds nerves need for efficient communication.  In the 
central nervous system, (CNS) the production and maintenance of myelin is the responsibility 
of cells called oligodendrocytes. Without normal myelination and healthy oligodendrocytes, 
AP conduction becomes slow and inconsistent, causing myriad neurological symptoms. In 
addition, axons can become damaged in the absence of myelin (Ferguson et al., 1997).  
 The significance of myelin is highlighted by the severity of myelin disorders.  In 
order to study demyelinating diseases like multiple sclerosis (MS), many model systems have 
been developed.  Several therapeutic approaches to myelination problems can be tested on 
these models.  Since myelin problems are necessarily oligodendrocyte problems, therapies 
focusing on these cells are promising.  Damaged or dead oligodendrocytes can be replaced 
either by promoting the growth and differentiation of endogenous oligodendrocyte progenitor 
cells (OPCs), or by directly injecting either OPCs or immature oligodendrocytes into the 
damaged CNS (Blakemore and Irvine, 2008).   
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 It was during the study of the remyelinating capacity of endogenous stem cell 
populations in a cuprizone model of demyelination that the idea for the present study arose.  
Cuprizone is one of several toxin-based methods for inducing and studying demyelination.  It 
is theorized that cuprizone selectively kills oligodendrocytes because of their high metabolic 
demand (Matsushima and Morell, 2001).  We hypothesized that, if oligodendrocytes have a 
susceptibility to the toxin because of their energy demand, then developing oligodendrocytes 
would also be vulnerable because, in addition to being in the oligodendrocyte lineage, their 
metabolism is taxed by growing, dividing, developing, and migrating.  We proceeded to 
investigate the oligodendrocyte precursor populations to determine their response to a 
demyelinating regimen of cuprizone.   
In order to realize the relevance of this idea, an understanding of myelin and its 
function and formation is necessary.  Consequently, in this thesis, I shall describe the 
importance of OPC populations in remyelinating the adult CNS.  This requires a discussion 
of myelin and the cells associated with it.  The nature of demyelination and remyelination as 
well as the models for studying myelin pathologies will also be introduced because myelin 
diseases represent a major class of neurological disorders.   
1.1 Myelin Structure and Function in the CNS 
 Myelin is a specialized cell membrane that is wrapped around axons in many closely 
apposed lamellae forming a structure called the myelin sheath.  Myelin is literally an 
extension of the cell membrane of the myelinating cell, either a Schwann cell in the peripheral 
nervous system or an oligodendrocyte in the CNS.  Unusual for a cell membrane, the dry 
weight of myelin is composed of a ratio of 70% lipid to 30% proteins, whereas most cell 
membranes are higher in proteins than in lipids (Baumann and Pham-Dinh, 2001). Also, 
because of its tightly wrapped configuration, there is very little cytosol and water associated 
with myelin (Bunge, 1968). 
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Along the length of a given axon, myelin sheaths are arranged segmentally, with short 
exposed regions between them.  These regions between myelin segments are called Nodes of 
Ranvier (Bunge, 1968) (see Figure 1). In the peripheral nervous system, usually only one 
segment is associated with one Schwann cell, but in the CNS, several myelin segments on 
many axons can be continuous with a single oligodendrocyte.  Oligodendrocytes have been 
known to myelinate up to 50 axon segments with the unfortunate corollary that killing one 
oligodendrocyte can cause widespread effects (Baumann and Pham-Dinh 2001). In 1928, Pio 
del Rio Hortega characterized the oligodendrocyte as the cell responsible for myelination in 
the CNS, but the physiological function of myelin was not determined until 20 years later 
(Huxley and Stampfli, 1949). 
In most vertebrates, myelination is necessary for attaining the impulse conduction 
velocities required for a nervous system to be useful.  Without myelin, nature’s best means of 
increasing conduction velocity is to increase axonal caliber.  Cable theory predicts that 
increasing diameter reduces resistance and increases velocity (Shepherd, 1994). In order to 
achieve usefully short times from stimulus to perception to response, very large axons would 
be required.  Anatomical restrictions make this unfeasible.   
 With myelination, the neuron achieves high speeds without unreasonably increasing 
the diameter.  In a myelinated neuron, electrically insulating myelin is wrapped several times 
around the axon, drastically increasing resistance and decreasing capacitance across the 
axonal cell membrane. The result of this is that current in the cytoplasm flows rapidly down 
the axon to the next node instead of flowing across the axolemma as it does along a naked 
axon (Shepherd, 1994). In this case, the transmembrane currents that are the action potential 
appear to jump down the axon, skipping internodes. This  
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Figure 1. Oligodendrocyte and Myelin Structure and Organization. 
 
An oligodendrocyte (O) can have many processes which wrap axons in multilayered 
sheaths of myelin (M).  The myelin-wrapped portion of an axon is termed the internode (I) 
while the exposed axon is called the node of Ranvier (N).  To achieve high signal 
conduction velocities, action potentials jump from node to node across internodes in a 
process called saltatory conduction.  A single oligodendrocyte may ensheath as many as 50 
axonal segments.  (modified with permission from Baumann, 2001). 
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saltatory conduction, in which action potentials jump quickly from one node to the next, is the 
key to achieving high conduction velocities (Stampfli, 1954). Since myelin makes such a 
significant contribution to nerve impulse conduction, it is worth looking at the cells producing 
it.  
1.2 Oligodendrocytes and their Origins: 
The myelinating oligodendrocyte is the end product of a series of maturational 
progressions.   Multipotential neural stem cells, properly guided by molecular cues, can 
develop into oligodendrocytes (Nait-Oumesmar et al., 2007).  Neural stem cells differentiate 
into early oligodendrocyte progenitor cells with migratory capacity. The cells then progress 
through early and late progenitor stages at which point their fate is already determined; late 
OPCs can remain undifferentiated as adult progenitor cells, or they can further differentiate 
into premyelinating oligodendrocytes.  If needed, the premyelinating cells mature into 
myelinating oligodendrocytes; otherwise, they may undergo apoptosis (Barres, 1992; Trapp 
et al., 1997). The stages of oligodendrocyte lineage can be loosely defined morphologically 
or by the unique sets of proteins they express, although precise discrimination among cells in 
the oligodendrocyte lineage is difficult (Trapp et al., 2004) (Figure 2).  
1.21 OPC Populations in the Adult CNS 
Since MS rarely affects the very young, developing brain, demyelination and 
remyelination usually involve mature oligodendrocytes and adult progenitors (Wood and 
Bunge, 1991). Because of this, the oligodendrocyte lineage and the sources of early OPCs in 
the adult are critical to remyelination.  There are several potential populations of early OPCs 
in the adult brain: The subventricular zone (SVZ), the subgranular zone (SGZ) of the dentate 
gyrus in the hippocampus, and the white-matter tracts such as the corpus callosum (CC) 
(Nait-Oumesmar et al., 1999; Palmer et al., 1997; Chang et al., 2004).  The OPC populations 
in the SVZ and white matter are well documented, and neural stem cells from the SGZ are a 
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potential source of oligodendrocytes because they have been shown to differentiate into 
oligodendrocytes in vitro (Doetsch et al, 1997; Gensert and Goldman, 1996; Palmer et al., 
1997) (Figure 3). 
The SVZ is located in the lateral walls of the lateral ventricles and is well known for 
being a significant site of neurogenesis and gliogenesis during development. The SVZ retains 
these properties into adulthood (Doetsch et al., 1997, Paterson et al., 73).  A histological 
study of the SVZ found that, excluding the ependymal cells lining the ventricles, as many as 
15% of the cells in the SVZ of rats are putative precursor cells (Doetsch et al., 1997).  It has 
also been established that that SVZ precursors respond to demyelination by dividing, 
migrating, and maturing into oligodendrocytes (Nait-Oumesmar et al, 1999). 
 The corpus callosum and some other subcortical white matter also contain cells 
capable of differentiating into myelinating oligodendrocytes (Gensert and Goldman,  
1996). There is also a thin, expansive, germinal layer just deep to the caudal aspect of the 
corpus callosum (Seri et al., 2006).  In development, migrating OPCs move into the white 
matter tracts, and, if they do not die or develop into mature oligodendrocytes, enter a quiescent 
state as adult progenitors (Levine et al., 2001).  These cells can be likened to satellite cells in 
muscle in that they have been shown to respond to myelin damage and mature into 
myelinating cells.  
The remaining candidate pool of remyelinating cells lies in the hippocampus.  The 
subgranular zone of the dentate gyrus is a site of adult neurogenesis (Kempermann, 1997).  
Additionally, investigation has shown that the SGZ cells producing neurons are multipotential 
stem cells.  That same study showed that the SGZ derived stem cells can be induced in vitro 
to differentiate into glia (Palmer et al, 1997). For this reason, the SGZ is treated here as a 
population with the potential to remyelinate. 
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Figure 2.  Oligodendrocyte Lineage 
 
Oligodendrocyte progenitor cells in the adult arise from generative zones in the 
brain such as the subventricular zone (SVZ).  These early progenitors can migrate 
throughout the CNS and differentiate into either myelinating oligodendrocytes or 
quiescent adult progenitor cells.  (Adapted from Trapp et al., 2004). 
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Figure 2.  Oligodendrocyte Lineage 
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Figure 3.   Proliferative Zones of the Adult Mouse Brain 
 These sagittal and coronal mouse brain sections highlight the regions of interest to 
the present study.  In the nissl-stained sagittal section, A, the corpus callosum is 
shown in green, the SVZ in blue, and the SGZ in red.  Vertical lines b and c 
indicate the level of section shown in the coronal sections of the SVZ and the SGZ 
respectively.  Line d indicates the level at which tissue was sectioned to evaluate 
myelin levels from the corpus callosum.  The coronal images are half nissl-stained 
sections and half schematic representations. In B, the SVZ is highlighted in blue on 
the nissl side. In C, the SGZ is the dark wedge seen in the in red box on the nissl 
side. (Modified from the Allen Brain Atlas, 2009). 
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These regions all have mitotic cell populations. Studies have shown that CNS insults  
such as penetrating or diffuse brain injuries or even ischemic events cause the number of 
dividing cells found in these areas to increase significantly relative to baseline levels 
(Chirumamilla, 2002; Zhang, 2001).  It has even been documented that the SVZ shows 
evidence of increased numbers and proliferation of OPCs in human multiple sclerosis 
patients (Nait-Oumesmar et al., 2007).  This understandable response to most insults 
suggests that the cuprizone model would also elevate the numbers of these cells, but the 
hypothesis being tested here predicts that cuprizone may suppress the expected proliferative 
response to demyelination.  
1.3 Multiple Sclerosis and Myelin Diseases: 
  Myelin diseases are an unfortunately common cause of neurological deficits.  Myelin 
diseases can be dysmyelinating conditions in which myelin is never formed fully or correctly 
in development, or they may be demyelinating diseases that cause the disruption or 
elimination of previously healthy myelin (Powers, 2004). Demyelinating disorders are the 
subject of this discussion; in the spectrum of these myelin disorders, multiple sclerosis is the 
most prevalent.   Estimates indicate that 400,000 individuals live with MS in the United States 
and that there may be as many as 2.5 million people suffering from MS worldwide (Who 
Gets MS, 2009). 
 Multiple sclerosis is a chronic demyelinating condition afflicting the CNS.  In MS, 
lymphocytes attack the myelin, demyelinating bundles of axons (Compston, 2008).  Loss of 
myelin and the concomitant axon damage lead to inconsistent, slow nerve conduction (Irvine 
and Blakemore, 2008). Once an axon is demyelinated, remyelination can be slow, incomplete, 
temporary or non-existent, leading to severe and long-term deficits (Compston, 2008).   
Demyelinating diseases, especially MS, are marked by the presence of sclerotic plaques 
throughout the CNS, hence the name multiple sclerosis. These plaques are the final result of 
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the processes of inflammation, demyelination/remyelination, oligodendrocyte death, and 
astrocyte reactivity (Raine, 1997).   
Since plaques can form all over the brain and spinal cord, there is a very wide range of 
neurologically based symptoms.  Individuals are uniquely affected by MS, and so the set of 
symptoms can vary significantly from one person to another.  Some of the more common 
symptoms that are frequently seen with MS are: cognitive impairment, changes in affect, loss 
or impairment of vision, clumsiness and poor balance, tremors, vertigo, sexual dysfunction, 
weakness, and pain (Whitaker and Mitchell, 1997).   
In addition to a wide range of symptoms, MS can present with different courses of 
progression, and in 1996, an international survey defined four prominent categories: 
progressive relapsing, secondary progressive, primary progressive, and relapsing-remitting 
(Lublin and Reingold, 1997).  The most common course the disease takes, about 85% of 
cases, is the relapsing remitting form in which patients suffer from acute attacks of declining 
neurological function, relapse, followed shortly by sometimes full recovery, remission, with 
relatively little progression between episodes (What Is Multiple Sclerosis, 2009).  The 
diversity of courses the disease can follow hints at the elusiveness of the etiology of MS.  
 The cause of MS remains unclear, even in the face of significant research efforts.   It 
is clear, however, that both environmental factors and genetic susceptibility lead to MS.   
There are distinct trends in MS cases around the world that speak to a geographical and 
possibly ethnic/racial/genetic influence.  Tropical areas have a very low incidence of the 
disease while MS has a higher occurrence in Europe and Canada. (Mathews, 1993)  At the 
same time, there is a twenty percent inheritance rate within families, strong enough to 
implicate genetics (Compston, 2008). Typically, MS occurs in non-tropical people between 
late childhood and early middle age and it occurs preferentially in women (Mathews, 1993). 
 With an estimated 2.5 million cases of multiple sclerosis around the world, it is 
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reasonable to say that it is a problem that demands substantial research.  The majority of MS 
patients have the relapsing-remitting form, and even the other types often evolve from a 
relapsing-remitting pattern (Who Gets MS, 2009). Each relapse, each debilitating attack, 
results from the demyelination of important tracts in the CNS. The fact that there is recovery 
or improvement of lost functions indicates that there is also remyelination (Raine, 1997).  
This has been confirmed with MRI and post-mortem histology (Raine, 1997). Therefore, in 
studying multiple sclerosis, it is as important to investigate remyelination as demyelination. 
1.4 Demyelination Models: 
Since MS is such a prevalent neurological disorder, several animal models have been 
developed to facilitate research into the nature and treatment of MS as well as other myelin 
disorders.  Miller et al. outline three main types of demyelination/remyelination model: 
autoimmune, virus-induced, and toxin induced (Miller et al, 1996). The common autoimmune 
model is experimental autoimmune encephalomyelitis (EAE). While there are others, the most 
frequently used virus-induced models are mouse hepatitis virus (MHV) and Theiler’s murine 
encephalomyelitis virus (TMEV).   Toxins commonly used to study myelin disorders are 
ethidium bromide, lysolecithin, and cuprizone (Miller et al., 1996). 
1.41 Experimental Autoimmune Encephalomyelitis: 
Experimental autoimmune (sometimes allergic) encephalomyelitis is a disease in 
which the T-cell mediated immune response is targeted to myelin specific antigens (Martin et 
al., 1992).  Acute and chronic forms of EAE cause variable demyelination. Chronic EAE can 
be characterized by a relapsing and remitting time course (Raine et al, 1988).  EAE is used to 
study inflammatory demyelination and spontaneous demyelination and remyelination. Its use 
has lead to immune-based MS therapies (Miller, 1996). The inconsistent and unpredictable 
demyelination seen with EAE hinders its usefulness as a model.  Also, the involvement of the 
immune system adds a complicating layer to the interpretation of myelination events resulting 
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from EAE (Matsushima and Morell, 2001).  
 
1.42 Virus-Induced Models 
There are several viruses that cause demyelination in animals.  In mice, mouse 
hepatitis virus, (MHV), Theiler’s murine encephalomyelitis virus, (TMEV), herpes simplex 
virus, vesicular stomatitis virus, and Semliki forest virus have all been used to study 
demyelination (Miller, 1996).  While viruses have been associated with demyelination events 
in humans, no virus is known to be linked to MS (Cook et al., 1995). Still, TMEV and MHV 
are commonly used as remyelination models.  
Though it is usually associated with the liver, as the name suggests, some strains of 
mouse hepatitis virus infect the CNS and induce demyelination. MHV is commonly chosen 
for studies involving the immune response to infection and demyelination in the CNS 
(Matthews et al., 2002). Similarly, Theiler’s murine encephalomyelitis virus is used, like 
MHV and EAE, to study the immune response to demyelination.  TMEV is an unusual, and 
useful, virus because it causes chronic infection.  The myelin disrupting effects of infection 
start early (in susceptible strains) and can fall into a relapsing-remitting pattern. (Dal Canto, et 
al. 1995).   
1.43 Toxin-induced models 
Unlike the above model systems in which demyelination is caused by the immune 
system, the toxin-induced models do not depend on the inflammatory response of the 
immune system for demyelination. Ethidium bromide, lysolecithin and cuprizone are 
compounds widely known and studied for inducing demyelination. The toxins act directly on 
myelin or oligodendrocytes (Miller, 1996). 
 Injection of lysolecithin very quickly achieves local demyelination, acting in as little 
as 30 minutes post-injection.  The myelin sheath is directly destroyed by lysolecithin, 
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attracting an inflammatory macrophage response.  Remyelination is spontaneous and begins 
when the myelin debris is cleared and finishes in a matter of weeks. (Hall, 1972).  
Alternatively, ethidium bromide and cuprizone induce demyelination by killing 
oligodendrocytes.  Like lysolecithin, local injection of ethidium bromide causes short-lived 
demyelination followed by spontaneous remyelination (Yajima, and Suzuki 1979).  Unlike 
lysolecithin and ethidium bromide, cuprizone is administered via ingestion and induces a 
predictable demyelination schedule over several weeks.  Remyelination ensues promptly upon 
discontinuation of cuprizone treatment (Blakemore, 1973).  In toxin-induced models of 
demyelination, remyelination is usually quick and effective, except with long-term, several-
month, administration of cuprizone, after which remyelination is often slow and incomplete 
(Matsushima and Morell, 2001). Because demyelination is not mediated by the immune 
system in these models, toxins are used to study the glial aspects of demyelination and 
remyelination without the complicating factors of lymphocytes and a breached blood brain 
barrier (Blakemore and Franklin, 1991; Ludwin, 1988).   
1.5 The Cuprizone Model 
Cuprizone (bis-cyclohexanone-oxaldihydrazone) is a copper chelator that is well 
established for use as a toxic model of demyelination and remyelination. Cuprizone is used in 
chemistry for its chelating properties, and the myelin pathologies seen in cuprizone toxicity 
are assumed to be the result of this action, though this remains unproven (Matsushima and 
Morell, 2001). Irrespective of its mechanism, Oligodendrocytes are thought to be the only 
CNS cells susceptible to cuprizone (Blakemore, 1973; Komoly et al 1987).  In addition to 
demyelination, feeding an animal cuprizone can cause spongiform encephalopathy, 
hydrocephalus, formation of megamitochondria in the liver, and changes in the activity of 
copper-dependent enzymes such as cytochrome oxidase.  Chelating copper to cuprizone prior 
to administration prevents these pathologies, which suggests that it is this property that is 
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responsible for the action of cuprizone (Matsushima and Morell, 2001). The question cannot 
be considered answered however, because treating cuprizone-intoxicated animals with excess 
copper does not prevent or relieve the pathologies (Carlton, 1967). 
 Nevertheless, the fact that metabolic pathways requiring copper are disturbed by 
cuprizone indicates that it may be metabolic insufficiency that leads to demyelination and 
oligodendrocyte death (Komoly, 1987).  This theory is widely held because the 
oligodendrocyte has a high metabolic demand as it maintains the relatively vast expanses of 
membrane contained in its branches and their sheets of myelin (Matsushima and Morell, 
2001).   Beyond this, it is not known why oligodendrocytes are so prominently susceptible to 
cuprizone.  It is from the notion that oligodendrocytes are especially affected by the metabolic 
disruption from cuprizone toxicity that the hypothesis tested here, that OPCs may also be 
susceptible, arose. 
 Regardless of its uncertain mechanism of action, cuprizone intoxication has proven to 
be a very useful means of studying demyelinating and remyelinating events.  It has 
advantages over autoimmune and virus-induced models because it is simpler and more 
consistent. Additionally, cuprizone creates a more widespread and reliable demyelination than 
other toxins.  It is considered an excellent model for consistent, predictable, and quantifiable 
demyelination and remyelination.  
 EAE and the virus models are known to produce spatially and temporally 
unpredictable lesions. This inconsistency makes quantification and comparison across 
individuals difficult (Matsushima and Morell, 2001).  Cuprizone is free of this problem; 
administration of cuprizone by ingestion consistently induces extensive demyelination in the 
corpus callosum and the superior cerebellar peduncles, making comparisons among animals 
more direct and meaningful (Ludwin, 1978).  Another advantage cuprizone has over the 
immune models is that it creates a much simpler system with fewer variables, perhaps since 
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the blood brain barrier remains intact (Bakker and Ludwin, 1987).  The immune involvement 
associated with EAE, MHV, and TMEV, while very useful in its own right, clouds the glial 
events of demyelination and remyelination with inflammatory compounds, cytokines, 
antibodies, and lymphocytes that may have their own effects on the processes being studied 
(Matsushima and Morell, 2001).     
  In addition, cuprizone intoxication can be used to cause a predictable course of 
demyelination over time, with a consistent remyelination following recovery with a cuprizone-
free diet (Blakemore, 1973; Mason et al., 2001).  Cuprizone can also be used to study chronic 
lesions that struggle to remyelinate (Mason, 2004). Lysolecithin and other toxic models of 
demyelination are very limited in this respect. These models all have their advantages though. 
In fact, the things highlighted as flaws in some contexts may be the very reasons why 
investigators with slightly different specific aims may prefer them to cuprizone, but for 
simply studying the events involved in the destruction and replacement of myelin, cuprizone 
historically stands out as the model of choice.  Because of this, the cuprizone model has been 
frequently used to study oligodendrocyte progenitor cells, therapeutic approaches to 
remyelination, the effects of demyelination on axons, and the characterization of 
demyelination, with substantial results. (Nait-Oumesmar, 1999; Blakemore and Irvine 2008; 
Irvine and Blakemore 2008; Ludwin, 1988). 
1.51 The Cuprizone Model in C57BL/6 Mice 
The present study was conducted using cuprizone toxicity in C57BL/6 mice.  This 
strain is a good choice because it offers the potential for gene function studies, but there are 
many other reasons for choosing this strain.  Cuprizone toxicity has been well-studied in 
C57BL/6 mice ranging from weanling to aged, and with various doses and durations of 
treatment (Matsushima and Morell, 2001).  These studies provided the information for 
choosing an age, dose and time course for the present work. 
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 A dose of 0.2% cuprizone in mice causes demyelination without unnecessary side-
effects such as dangerous weight loss.  Higher doses that have been used in past studies, 
such as 0.5 and 0.6% cuprizone have unreasonably high rates of mortality and complications 
(Matsushima and Morell, 2001).  Corresponding with cuprizone toxicity in other animals, the 
resulting demyelination is extensive and consistent in the CC and superior cerebellar 
peduncle (Ludwin, 1978).  The timeline for demyelination is also consistent. Demyelination 
begins within the first week of exposure and progresses until major losses of myelin are seen 
in the 4th week.  Removal from cuprizone in the fifth week allows a substantial remyelination 
of the damaged tracts by the 8th week (Mason et al., 2000).    
Since it is used to study remyelination, the response of the OPC populations to the 
cuprizone model is a pertinent line of research.  The study presented in this thesis does just 
that.  Oligodendrocytes are especially sensitive to the toxic effects of cuprizone. If this is 
because the energy required to maintain a mature oligodendrocyte is not available due to the 
copper chelating effects on the mitochondria, then progenitor populations, which should have 
a high demand for energy as well, may also be highly susceptible. If oligodendrocytes are 
selectively killed because of some particular aspect of their biochemical character, then 
perhaps it is also true that the cells oligodendrocytes are derived from will have the same 
inherent susceptibility.  With these ideas as a foundation, this study was designed to 
investigate the cuprizone toxicity model for its effects on the proliferative cells in the SVZ and 
SGZ.     
 In order to uniquely investigate proliferating cells, they must be able to be identified. 
Bromodeoxyuridine (BrdU) was chosen for identifying the proliferative cells in the SVZ and 
SGZ. BrdU is a thymidine analog that competes with thymidine during DNA synthesis.  As a 
result, cells that undergo mitosis in the presence of BrdU incorporate it.  These cells can then 
be labeled immunohistochemically (Miller and Nowakowski, 1988).  BrdU incorporation and 
immunocytochemical identification of dividing cells form the basis for the current study. 
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2 
Using Immunohistochemistry to Evaluate the Effects of the Cuprizone Model on the 
Proliferative Cell Populations of the Adult Mouse 
 
 
In order to test the response of oligodendrocyte progenitors (OPCs) residing in the 
SVZ and SGZ to cuprizone over time, test groups of male C57/BL6 mice (The Jackson 
Laboratory) were established according to dose and time point.  Both the doses and the 
time points were chosen on the basis of previous work showing the severity and course of 
demyelination and its repair in the cuprizone model (Mason et al., 2001). Doses of 0.2%, 
and 0.3% cuprizone were tested at 1 (3 animals at 0.2%; 5 animals at 0.3%), 3 (3 animals 
at each dose), or 5 weeks of treatment (3 animals at each dose), or 8 weeks with a 3-week 
recovery after a 5-week treatment (3 animals at 0.2%; 2 animals at 0.3%). Control animals 
were established at 0 (4 animals) and 8 weeks (3 animals) on ground chow without 
cuprizone (Table 1).  Additionally, to evaluate the effectiveness of the demyelinating 
model, animals were also treated in order to evaluate the extent of demyelination in 1µm 
and 90 nm sections.   
2.1 Cuprizone Treatment 
The mice were allowed 1 week to acclimate to the AAALAC accredited Virginia 
Commonwealth University Division Animal Resources room before beginning the  
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Table 1.  Numbers of Animals in Each Treatment Paradigm 
Ten test groups of male C57/BL6 mice 6 weeks old were established: 2 control 
groups, and 8 experimental groups. The control animals were given no cuprizone, 
but ground chow, for either  0 or 8 weeks. Experimental animals were fed ground 
chow containing either 0.2 or 0.3% cuprizone.  These animals were divided into  1, 
3, 5, and 8 week groups.  The 8-week animals were fed chow without cuprizone for 
the final 3weeks. 
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 0-Week 1-Week 3-Week 5-Week 8-Week 
0 % 
Control 
4 0 0 0 3 
0.2% 
Cuprizone 
0 3 3 3 3 
0.3% 
Cuprizone 
0 5 3 3 2 
 
Table 1.  Numbers of Animals in Each Treatment Paradigm 
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treatment regimen at 6 weeks of age.  The administration of cuprizone was accomplished 
by mixing the neurotoxin into their food. The food was prepared by adding the appropriate 
mass of cuprizone to ground rodent chow (Harlan).  Homogeneity of the cuprizone mixture 
was achieved by 5 minutes of vigorous shaking to prevent the mice from selectively avoid 
the cuprizone.   The animals were checked and fed 6 times a week. At each feeding, the 
food jars (5.5cm x 6.5 cm) were refilled to their 100-g capacity. In addition, the animals 
were weighed weekly to monitor for dangerous weight loss.   
2.2 BrdU Injection 
48 hours prior to the end of their treatment paradigm, the animals received a single 
intraperitoneal injection with BrdU in order to label dividing cells. The dose chosen for the 
injections was 300 mg/kg body weight. Cameron and Mckay compared many BrdU doses 
and found that lower doses labeled fewer cells and higher doses did not label any more 
cells (Cameron and McKay, 2001).  The BrdU was dissolved in a solution of .007 M 
NaOH in 0.9% (normal) saline and injected intraperitoneally (Cameron and McKay, 2001). 
After the injections, the mice remain on cuprizone until they are sacrificed.  
2.3 Immunohistochemical Processing for Flourescence: 
2.31 Perfusion 
In order to harvest brain tissue for processing, the animals were perfused and their 
brains dissected.  Intraperitoneal injection of Avertin (2,2,2 tribromoethanol (Sigma-
Aldrich) in a solution of 1% tert-amyl alcohol in 1x phosphate buffered saline (PBS)) was 
used to anesthetize the animals for the procedure.   Once sufficiently anesthetized, 
transcardiac perfusion was performed with 0.9% saline at 5ml/min. Once a perfusion was 
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complete, the skull was opened and the brain removed.  Immediately, the brain was frozen 
by submergence in a -25°C bath of 2-methylbutane.   The frozen brains were removed 
from the bath and briefly stored, individually wrapped in aluminum foil, at -20°C until 
sectioning. For each animal, the liver was removed and frozen in the same manner as the 
brain.  The livers were harvested to serve as a positive control for BrdU. 
2.32 Sectioning 
The brains were sectioned to allow for the microscopic evaluation of the SVZ and 
SGZ.  Coronal sections were cut at a thickness of 40µm using a Leica CM 1850.  3 series 
of sections were collected starting at the anterior reaches of the lateral ventricles where the 
white matter tracts become arcuate and proceeding to the posterior extent of the dentate 
gyrus of the hippocampus.  In each series, every 5th section was collected on charged 
slides. For each animal, an average of 14 sections were collected for the SVZ and 8 
sections for the SGZ per series.  
2.33 Staining 
For evaluation of BrdU, the sections were fixed in 4% paraformaldehyde for 15 
minutes, washed (3 times for 5 minutes each) in 1x PBS, then soaked in 3N HCL for 30 
minutes to denature nucleic acids, which makes the BrdU epitope accessible to antibodies.  
Another thorough PBS wash preceded blocking the sections in a block solution of PBST 
(0.4 % Triton X-100 (Sigma) in 1x PBS) containing 4% normal goat serum for 1 hour.  
Upon completion of blocking, the sections were incubated overnight at 4°C with 
monoclonal mouse antibody against BrdU (Dako) at a concentration of 1:200 in block 
solution.  
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    In order to visualize the BrdU, the primary antibody was thoroughly washed off with 
PBST immediately prior to incubation in a fluorescent goat anti-mouse secondary antibody 
(Alexa Fluor 488) at 1:400 in block solution. After incubating at room temperature for 2 
hours, the sections were washed first with PBS then with deionized water before being 
coverslipped with Vectashield mounting medium (Vector Laboratories) to enhance and 
preserve fluorescence.  The slides were then stored at 4°C.  
2.34 Quantification 
     The proliferative response of cells in the SVZ and the SGZ to cuprizone treatment was 
evaluated by counting BrdU labeled cells in those regions with fluorescence microscopy.  
Using an Olympus BX-51 at 40x, every BrdU+ cell in the animal’s right SVZ and the 
ipsilateral SGZ was counted manually in each section. For objectivity and consistency, the 
SVZ and SGZ were counted from the same side of the brain (right) in each section for 
every animal. 
2.4 Processing for Semi-thin and Thin Sections: 
2.41 Perfusion and Fixation 
 The mice were anesthetized as above for transcardial perfusion fixation for 0.5µm 
section processing.  Normal saline was used to flush the animals until the perfusate ran 
clear.  This was followed by 5 ml/min perfusion with a fixative solution of 0.1M Millonigs 
phosphate buffer (pH 7.3) containing 5% glutaraldehyde (Electron Microscopy Sciences) 
and 4% paraformaldehyde (Electron Microscopy Sciences) for fixation.  The mice were 
perfused for 20 minutes after cessation of muscle twitches.  After perfusion, the brain was 
dissected and submerged in the fixative solution at 4°C for 2 weeks.  Then the brain was 
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soaked overnight in 0.1M cacodylate buffer (Electron Microscopy Sciences) to remove 
excess aldehydes.  
2.42 Tissue Processing 
 The whole brain was bisected mid-sagittally and the right hemisphere embedded in 
agarose to be sectioned. Four (4) 500µm sections were cut coronally on a Leica VT 1000s 
vibratome.  Corresponding 500µm sections were selected from each brain. Each section 
was then rinsed in cacodylate buffer and post-fixed in 1% osmium tetroxide (Electron 
Microscopy Sciences) for 1 hour while being constantly agitated.  The post-fix was 
followed by 3 rinses in cacodylate buffer then dehydration in serial dilutions from 30% to 
100% ethanol at 4°C.  Each section was incubated twice for twenty minutes each in 
propylene oxide and then the tissue was left overnight in a mixture of one part PolyBed 
(Polysciences, Inc.) and one part propylene oxide according to the manufacturer’s protocol. 
The next day, each section was embedded in fresh PolyBed resin. The resin blocks were 
polymerized in an oven at 55°C for 48 hours and sectioned to 0.5µm on a Leica EM UC6 
microtome.   
2.43 Staining and Imaging for 0.5 µm Sections 
 The 0.5µm sections were stained with a toluidine blue solution.  To make the 
staining solution, 0.1g each of Toluidine Blue O (Fisher Scientific, Inc.), Methylene Blue 
(Fisher Scientific, Inc.), and Azure II (Polysciences, Inc.) are added to 1% sodium borate 
in distilled water, mixed well, and filtered.  The 0.5µm sections are allowed to dry on 
slides resting on a hot plate at 60°C.  While on the hot plate, the slides are covered with the 
toluidine blue solution for 3-5 minutes until appropriate staining is achieved. Finally the 
27 
sections are rinsed in water, dried and coverslipped with Permount mounting medium. The 
sections were examined in bright field at 100x with a Nikon Eclipse 800 light microscope. 
Images were captured from this scope with an RT sliding spot scope from Diagnostic 
Instruments, Inc.  
2.44 Staining and Imaging for 90nm Sections 
Resin blocks are prepared as above and a PolyBed block is cut to 90nm on a Leica 
EM UC6 microtome.  The sections are collected on EM grids. The grid with the section is 
allowed to dry before being stained.   The grids are placed in a solution of 5% uranyl 
acetate in 50% methanol for several minutes, rinsed 3 times in distilled water, carefully 
blotted dry, and placed in filtered Reynold’s Lead Citrate solution. After several minutes in 
Reynold’s the stained sections are allowed to dry. These 90nm sections were analyzed 
using a JEM1230 transmission electron microscope (JEOL Ltd.) equipped with a Gatan 
Ultrascan CCD camera (Gatan, Inc.).  
2.45 Quantification 
 Saggital images of the corpus callosum at the level of the branching of the fornix 
were evaluated for myelination levels.   The number of myelinated axons was counted 
individually from each image. 
2.5 Data Analysis 
The BrdU+ cell counts were reported for each section from the rostral extent of the SVZ to 
the caudalmost reaches of the SGZ.  For every animal, the number of BrdU+ cells counted 
in each section was averaged for the SVZ and the SGZ.  These data, reported as 
BrdU+cells per section, underwent statistical analysis.  Each treatment group was 
28 
compared to the control group using a Student’s t-test against the null hypothesis that 
experimental values do not differ from control values.  Also, the myelinated axon counts 
were analyzed.  The counts were reported as the number of myelinated axons per field.  
The data for each treatment were compared to the control levels using t-tests.
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3 
The Cuprizone Model Affects CNS Cells Other Than Mature Oligodendrocytes 
 
 
3.1 Demyelination and Remyelination of the Corpus Callosum  
This research focuses on the cuprizone model for toxic demyelination.  Previous 
work from many labs has shown that cuprizone causes consistent and substantial 
demyelination in the major white matter tracts of the CNS.  Using this toxin in C57BL6 
mice should therefore yield a decrease in myelin wrapped axons in the corpus callosum. 
High magnification (1000x) inspection of 1 µm mid-sagittal sections of the corpus 
callosum at the level of the fornix (see line d in Figure 3) shows that the cuprizone dosing 
regimens of 0.2 and 0.3% do cause obvious demyelination relative to control after 5 weeks 
(Figure 4).  Counts of myelinated axons confirm the apparent demyelination in the corpus 
callosum (Figure 4).  5 weeks of 0.3% cuprizone treatment is characterized by a 65% loss 
of myelinated axons from the control level of 3099 axons/field to 1087 axons/field. The 
images and the counts are also consistent with a remyelination event after 3 weeks without 
cuprizone.  There is a 117% increase from 1087 cells/field at 5 weeks to 2360 cells/field at 
8 weeks, restoring the corpus callosum to 76% of control levels (Figure 4).  Confirmation 
of demyelination was achieved by inspection at 8000x with electron microscopy      
(Figure 5).  
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Figure 4. Cuprizone-induced Demyelination in the Corpus Callosum 
 
Myelinated axons are counted in mid-sagittal sections of the corpus callosum at the 
level of the fornix, as illustrated by line d in Figure 3A. Control animals show high, 
consistent, and evenly distributed myelin levels, A.  Five weeks on 0.2% cuprizone 
causes demyelination and the number of myelinated axons is greatly reduced, B. 3 
weeks without cuprizone following a  5-week demyelinating cuprizone regimen 
allows remyelination as seen in C . The bar graph, D, illustrates that the number of 
myelinated axons per field decreases to 35% of control with cuprizone. When 
cuprizone is removed from the diet for three weeks the myelinated axon count 
recovers to 76% of control levels.  (Scale bar = 5 µm) 
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Figure 4. Cuprizone-Induced Demyelination in the Corpus Callosum 
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Figure 5. Electron Micrographs of Corpus Callosum  
 The apparent demyelination seen in the light microscopy images from which the 
myelinated axon counts were taken (Figure 4A-C) was confirmed with electron 
microscopy at 8000x. Image A shows control levels of myelination. EM shows a 
demyelination at 5 weeks on cuprizone, B, and a rise in myelinated axons after 3 
weeks of recovery, C. (Scale bar = 1 µm) 
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Figure 5. Electron Micrographs of Corpus Callosum  
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3.2 BrdU Immunohistochemistry:   
3.21 Cuprizone affects BrdU Incorporation in the SVZ 
Immunohistochemistry for BrdU allows the visualization of cells that have undergone 
mitosis after injection of the thymidine analog.  BrdU was injected 48 hours prior to 
sacrificing the animals to identify populations of dividing cells.  The use of a fluorescently 
tagged antibody to BrdU shows that cuprizone dramatically decreases the number of 
proliferative cells in the SVZ and SGZ. 
The control animals have an average of 117 BrdU+ cells per SVZ section.  In the control, 
the labeled cells are well distributed and fill the SVZ.  For both 0.2 and 0.3% doses in the 
SVZ, the number of BrdU+ cells drastically declines to less than 10% of control after just 1 
week of cuprizone treatment (Figures 6,7).   This result is significant with a p-value <5.0E-
6 relative to control.  All p-values here compare experimental values to control values in a 
Student’s t-test. Over the course of several weeks, the labeled population grows, showing 
more BrdU+ cells. After 3 weeks of cuprizone, 0.2%-treated animals exhibit an increase to 
65% of control (p<0.01) while 0.3% animals only recover to 19% of control (p<5.0E-5).  At 
5 weeks, the point of the most significant demyelination, the number of BrdU+ cells in the 
SVZ has returned to 88% of control levels at 0.2% cuprizone, and 63% at 0.3% (p<0.05).  
Yet, after 3 weeks of recuperation from cuprizone, the animals at both doses fail to recover 
entirely to control numbers with 0.2% cuprizone at only 61% of control and 0.3% reaching 
69% (p<0.005).  Both cuprizone doses induce the same trend, a drastic drop in BrdU+ cells 
followed by a slow and incomplete comeback; the difference is that the SVZ in 0.3% 
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treated animals remains suppressed longer, but ultimately 0.2% and 0.3% return to about 
the same level. (Figure 7).  
3.22 Cuprizone affects BrdU Incorporation in the SGZ 
BrdU incorporation was also investigated in the SGZ with cuprizone intoxication.  
The SGZ exhibits a response similar to that seen in the SVZ.  The SGZ response to 
cuprizone is shown in Figure 8.  As with the SVZ, BrdU labeling rapidly decreases to 
<10% of control (p<0.005) in the first week of cuprizone treatment for both doses. At 3 
weeks, 0.2% animals recover to a level not statistically significantly different from control 
(p=0.32) and even 0.3% animals rise to 43% of control (p<0.05).  After this increase the 
number of labeled cells at both treatments drops again by 5 weeks. Even after three weeks 
off of cuprizone, both doses remain below 30% of control.  This is in contrast with the 
modest recovery seen in the SVZ.     
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Figure 6. BrdU+ Cell Counts Fall Drastically After Only 1 Week on Cuprizone and 
Recover After 3 Weeks Without Cuprizone 
Under control conditions, the SVZ is well populated with BrdU + cells distributed 
throughout the zone, A. After 1 week of 0.3% cuprizone, B, the SVZ is nearly 
depleted of BrdU+ cells. C shows a significant recovery in the number of labeled 
cells 3 weeks after removal from a 5-week 0.3% cuprizone diet. D shows a nissl-
stained section through the lateral ventricle at the same level as A, B, and C to 
serve as a reference. scale bar = 100µm. 
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Figure 6.  BrdU+ Cell Counts Fall Drastically After Only 1 Week on Cuprizone and 
Recover After 3 Weeks Without Cuprizone 
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Figure 7.  The Number of BrdU+ Cells/Section in the SVZ Over Time for Each Dose 
Control animals average 117 cells/section.  1 week of cuprizone causes a steep 
decline to 9 cells/section for 0.2% (p<5.0E-6) and 6 cells/section for 0.3% (p<5.0E-
6) after three weeks on cuprizone, the levels are 76 cells/section for 0.2% (p<0.01) 
and 21 cells/section for 0.3% (p<5.0E-3).  5 weeks sees the highest levels for 0.2% 
at 104 cells per section (p<0.05), but 0.3% only reaches 71 cells/section at this 
point (p<0.05)  After three weeks without cuprizone, 0.2% animals show a decrease 
to 72 cells/section (p<5.0E-3) while there is no significant change between 5 and 8 
weeks for 0.3% 
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Figure 7.  The Number of BrdU+ Cells/Section in the SVZ Over Time for Each Dose 
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Figure 8.  The Number of BrdU+ cells/section in the SGZ Over Time for Each Dose 
 Cuprizone 
In the SGZ, control animals average 7 cells/section.  Like in the SVZ ,1 week of 
cuprizone also causes a steep decline in the SGZ to <1 cell/section for 0.3% 
(p<1.0E-3) and <2 cells/section  for 0.2%.  After three weeks on cuprizone, the 
count is 3.5 cells/section for 0.3% animals (p<0.05), but has increased to 6 
cells/section for the lower dose.  5-week and 8-week cell counts dwindle again to 
3.2 and 1.4 cells/section respectively for 0.3%(p<0.01). Similar counts are seen 
with 0.2% at these later time points.  
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Figure 8.  The Number of BrdU+ cells/section in the SGZ Over Time for Each Dose 
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4 
Cuprizone’s Effect on Cells in the SVZ and SGZ brings New Insights to the Use of 
the Model 
 
 
The novel findings presented here may have significant implications for the use of the 
cuprizone model. The cuprizone regimen followed does induce significant demyelination  
followed by remyelination, but it seems that cuprizone may have broader effects in the brain 
than previously believed. The BrdU data show conclusively that cuprizone impacts the 
dividing cells in the generative zones of the brain.  This is the first observation that 
cuprizone’s cellular effects in the adult brain are not limited to mature oligodendrocytes.  
This new finding has substantial repercussions on the interpretation of studies using the 
cuprizone model.   
4.1 Demyelination in the Cuprizone Model 
The clear loss and eventual recovery of myelinated axons as seen in 1µm sections 
stained with toluidine blue confirms the demyelinating/remyelinating action of the cuprizone 
model.  The demyelination and subsequent remyelination trends observed in the C57/BL6 
mice in this study are also in accord with the established timeline for the model (Mason et al., 
2001).  The cuprizone model did cause consistent, predictable demyelination in the current 
study.  As such, the cuprizone toxicity model is a good one for causing myelin disruption and 
loss.  However, the results of the BrdU experiments have implications that may restrict the 
utility of this popular model. 
4.2 Trends in the BrdU labeling of the SVZ and SGZ 
It would normally be expected that the introduction of a toxin and the associated 
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demyelination would cause an increase in the number and proliferation of progenitors in the 
SVZ and SGZ that may be concurrent with demyelination.  This is because most CNS 
insults, including demyelination, induce a well documented proliferation of cells in these areas 
(Chirumamilla, 2002; Nait-Oumesmar et al., 2007; Zhang et al., 2001). However, this study 
found that the response to cuprizone in the SVZ as evidenced by BrdU 
immunohistochemistry occurs very shortly after cuprizone administration.  Furthermore, in 
both 0.2% and 0.3% conditions, the SVZ response is an abrupt, steep decline in the number 
of cells incorporating BrdU.  After the drop seen in the first week, BrdU+ cells slowly 
become more numerous.  The number of the BrdU+ cells in the SVZ reaches the highest 
non-control levels after 5 weeks on cuprizone, and the population fails to recover further 
when the insulting cuprizone is removed from the diet.   
 While the trends for the two dosages are very similar they are not the same.  In the 
first week, the lower dose induces almost the same percent decrease in labeled cells as does 
0.3% cuprizone; average BrdU counts at both doses were within 3 cells of one another, and 
both were less than 10% of control levels.  At 3 weeks though,  0.2% cuprizone allows some 
recovery while the 0.3% treatment continues to suppress the number of labeled cells.  After 2 
more weeks, the 0.2% BrdU+ cell count reaches its highest point at 5 weeks, and then the 
number declines slightly after 3 weeks without cuprizone.  On the other hand, BrdU+ cell 
counts at 0.3% begin to rise more dramatically after the 3rd week, but do not change 
significantly after the 5th week. 
4.21 BrdU+ Cell Counts Initially Decrease Upon Cuprizone Administration 
At each dose, anti-BrdU labeling of cells in both zones examined shows a drastic 
decline in BrdU incorporation. The number of cells that label positive for BrdU after a single 
injection depends on the number of dividing cells and the rate of division, so any change in 
the number of BrdU+ cells could be attributed to several things. The decrease seen in BrdU 
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labeling does not specify exactly what cellular events are occurring in the SVZ and the SGZ, 
but it clearly shows that the cells in these areas do respond to cuprizone. It is possible that a 
large percentage of the cells labeled in the control condition could be dying because of the 
cuprizone.  Alternatively, the toxin may induce the cells to halt their cell cycle or at least to 
reduce their rate of reproduction.  Another possibility is that cells are migrating out of the 
counted areas.  
The effect of cuprizone on mature oligodendrocytes is commonly attributed to 
metabolic insufficiencies due to the copper chelating properties of the toxin (Matsushima and 
Morell, 2001). Cuprizone is known to interfere with copper-dependent enzymes that are 
necessary for ATP production (Suzuki, 1969).  This aspect of cuprizone intoxication, which 
is thought to kill mature oligodendrocytes, may be causing the trends revealed by the data 
obtained in this study. 
 The immature, dividing, cells of the SVZ and SGZ may be very vulnerable to 
metabolic insults.  A dividing cell must expend large amounts of energy to copy its genome, 
and to make enough proteins, organelles, and membrane to serve 2 daughter cells.  In addition 
to these things, new cells grow and sometimes migrate. These all serve to create a high 
demand for ATP, which may not be met in the presence of cuprizone.  Cells may die in 
response to a cuprizone-induced decrease in ATP production, or the cells may respond by 
decreasing their demand for energy, stopping or slowing cell division processes and entering 
G0, as is commonly seen in cells and organisms which do have the ability to become 
quiescent when the environment becomes inhospitable (Cook et al., 2000).   
Cell death, necrotic or apoptotic, could explain the observed change in BrdU+ cell 
counts.  The death of cells prior to the BrdU injection clearly prevents incorporation of the 
marker, but cells dying after the BrdU injection might not be labeled either. These cells may 
already have the thymidine analog in their DNA.  If this were the case though, the cells would 
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very likely still not label BrdU+ because necrotic and apoptotic processes result in the 
disassembly of the nucleus and digestion of the cell’s DNA (Nagata, 2000). The fragmented 
DNA of dead cells would therefore not be accounted for in counts of BrdU+ nuclei.  Only if 
the cell death occurs just prior to perfusion, before the DNA degrades, might BrdU still label 
cells that have died. Unfortunately, the possibility of cell death adds a complicating factor; 
BrdU has also been reported as an effective marker for DNA damage and apoptosis (Li, 
1995).  While this fact may complicate the interpretation of the results of the current study, 
one may also deduce that the loss of BrdU positive cells should not correlate with cell death. 
Another possible explanation for the drastic reduction in BrdU+ cells is a change in 
mitotic activity.  Before a eukaryotic cell can divide, it must make a second copy of the DNA 
contained in its nucleus.  This replication of DNA occurs in the S, or synthesis, phase of the 
cell cycle. It is because it competes with thymidine in DNA replication that BrdU acts as a 
cell proliferation marker (Miller and Nowakowski, 1988).  Perhaps the cells that are actively 
reproducing under control conditions simply fail to initiate the cell cycle or halt their progress 
through the cycle at some point.   
Clearly, BrdU will not label a cell that is no longer actively progressing through the 
cell cycle, but a cell that has only slowed down its division rate may also be exempt from 
incorporating BrdU.  This is because BrdU only remains available in the brain for as little as 
2 hours post injection (Cameron and McKay, 2001). Given the limited temporal availability 
of BrdU, only cells that happen to enter S phase during the critical period can incorporate the 
compound.  The slower the division cycle, the less probable it is that a given cell is in S phase 
while BrdU is available.  Because of this, merely slowing the rate of advancement through the 
cell cycle from 6 hours to 18 hours would have a dramatic effect on the number of labeled 
cells. 
Alternatively, there is another situation that may account for the loss of BrdU+ cells, 
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though it may not be a direct result of cuprizone on the dividing cells.  Migration of cells out 
of the examined areas would explain the observations made after 1 week on cuprizone.  
Migration is not a logical consequence of cuprizone on the OPCs or any other cells in the 
SVZ, but cuprizone may be indirectly triggering the migration of cells by causing other cell 
types to release signaling molecules.  While migration could cause a decrease in BrdU+ cell 
counts, the large percentage decrease and the short time frame are not indicative of a 
migration event.  Also, were the cells to migrate, cells outside the areas of interest would label 
BrdU+ and a qualitative observation of the nearby brain regions revealed that very few cells 
outside the SVZ and SGZ took up BrdU at 1 week.  
There are several possible explanations for the initial BrdU+ cell count reduction after 
1 week of cuprizone administration.  The mechanism of BrdU labeling itself does not 
necessarily favor one of these explanations over the others.  Although, the facts that BrdU can 
label apoptotic cells and no BrdU+ cells were seen outside the proliferative zones argue 
against apoptosis and migration.   Even without confidently knowing why the BrdU counts 
decrease, it is undeniable, given the strength of the statistical significance, that cuprizone has a 
drastic effect on the cell populations under investigation in the SVZ and the SGZ.  
4.22 BrdU+ Cell Counts Trend Back Toward Control Levels after Initial Decrease 
After the initial decline in BrdU+ cells, the labeled cell population in the SVZ begins 
to grow, even in the presence of cuprizone.  The reasons for this are not clear, but there are 
several possible explanations for the trends seen at each time point.  The explanations for the 
initial decreases have already been discussed, but they do not account for the trends seen at 3, 
5, and 8 weeks. As mentioned previously, the number of BrdU+ cells after a single injection 
depends on the number of dividing cells and the rate of division, so, for any time point after 
the initial decrease, changes in the number of BrdU+ cells could be attributed to several 
things.  Increases may be due to cells that were largely unaffected by cuprizone toxicity 
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reproducing or to cells that had arrested or slowed their cell cycles increasing their 
proliferation rates. Also, cessation of an apoptotic response or decreased migration could 
explain the resurgence in BrdU levels in the SVZ.  Decreases may be attributed, as with the 
decline seen at 1 week, to cell death, cell cycle arrest or retardation, or migration.  
At 3 weeks, the number of labeled cells counted increases from 1 week for both 
treatments, but the increase is much greater for 0.2% cuprizone.  Mason et al. have shown 
that there is oligodendrocyte apoptosis after 3 weeks of cuprizone treatment (Mason,  2000).  
The death of oligodendrocytes and the early stages of demyelination may chemically trigger a 
proliferative response in the immature cells.  The influence of these triggering factors may 
cause the cells that have survived cuprizone thus far to increase their division rate, causing 
more of them to take up BrdU.  These signals may not be strong enough to significantly 
overcome the toxic effects of cuprizone at the 0.3% dosage, explaining the differences in cell 
counts at this time point.   
At 5 weeks, the population of BrdU+ cells increases still further from 3 weeks and 
reaches its highest point in the 0.2% animals.  The 0.3 % animals also exhibit a strong 
increase from 3 weeks to 5 weeks. By this time, there has been apoptosis in the 
oligodendrocyte populations and the major tracts are largely demyelinated (Mason, 2000). 
The dying oligodendrocytes and the microglia clearing myelin debris could be very strongly 
signaling for the germinal zones to increase their proliferation rates.  With such extensive 
oligodendrocyte death and demyelination, the signals could be strong enough to overcome the 
effects of even 0.3% cuprizone, accounting for the increases seen in both treatment groups at 
5 weeks.   
The cuprizone regimen ends at 5 weeks, and the animals were allowed to survive for 3 
more weeks without the neurotoxin.   The BrdU+ cell counts do not increase dramatically 
without cuprizone. In fact, the 0.2% animals experience a significant decrease in the number 
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of labeled cells.  This trend was unexpected, but might not be that surprising.  At 8 weeks, 
remyelination is substantial, and there are no major apoptotic events.  After the 5-week time 
point, the signals for increased proliferation should dwindle.  It may be expected that the 
germinal populations would return to control levels with no cuprizone and no unusual 
signaling factors.  Instead, the level decreases at 0.2% (p<0.05) and the increase seen at 0.3% 
is not statistically significant (p=0.32).   
A population of dividing cells in an organism that is beyond developmental stages 
would not be expected to increase under normal conditions.  The cells in such a population 
should reproduce at a rate equal to the rate at which cells are lost.  If the populations that take 
up BrdU under control conditions follow such a paradigm, then it is not so unusual that there 
is not a full recovery to control levels when cuprizone is withheld from the diet.  Without 
cuprizone, the cellular environment could begin to return to normal.  In this case, it would be 
expected that the population would not show an increase from 5 weeks.  Even the decrease 
seen at 0.2% may be explained; the cells were dividing at an elevated rate, even with 
cuprizone, because of the molecular cues from the loss of oligodendrocytes and myelin.  
Removing cuprizone eliminates these cues and the rate of cell division returns to normal, 
decreasing from the elevated rate and accounting for the decrease in BrdU labeled cells seen 
at 8 weeks.  
Migration of cells away from the SVZ could also be responsible for the trend seen at 
the end of the treatment paradigm.  At 5 weeks, and during the subsequent recovery weeks, 
remyelination is an ongoing process; the oligodendrocytes killed by cuprizone must be 
replaced for there to be new myelin, so OPCs could be migrating from the SVZ to replace the 
oligodendrocytes directly, or moving in to replace the cells that do replace the dead 
oligodendrocytes.  Migration out of the SVZ would account for the apparent failure of the 
cells to recover from cuprizone.  If cells remove themselves from the SVZ via migration at a 
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rate similar to that of proliferation, there would be no increase. And if the cells migrate even 
faster, there may be a decrease, as is seen at 0.2% cuprizone.  It should be noted that, while 
migration is not easily ruled out as an explanation for the trends from 5-8 weeks, it is not 
likely to be the explanation for the initial decrease seen in week 1.  This is because many cell 
types could be taking up BrdU, and it is improbable that such a large majority of these cells 
would depopulate the area so soon, especially since migration requires significant energy 
expenditure.  Also, if the cells migrated there should be BrdU+ cells outside the SVZ and 
SGZ at 1 week, and there are not. 
4.3 Response of the SGZ to Cuprizone 
 Most of the discussion thus far pertains to the SVZ, but the BrdU levels observed in 
the SGZ suggest that the germinal zone in the hippocampus is also sensitive to cuprizone.  
The same explanations used for the initial SVZ response may largely account for the 
observations made in the SGZ, but, in vivo, the cells in the SGZ are thought to be exclusively 
neuronally-fated stem cells (Kempermann et al., 1997; Palmer et al., 1997). In culture, they 
have been molecularly guided toward differentiating into glia (Palmer et al, 1997).  However, 
in the first week of cuprizone treatment, there should be no signals directing these cells into 
the oligodendrocyte lineage.  Yet these cells do show the same drastic decrease in BrdU 
labeling that is seen in the SVZ.  This indicates that even dividing cells without glial-restricted 
fates are affected by cuprizone. The BrdU+ cell counts in the SGZ do not recover to any 
great extent at 5 or 8 weeks as seen in the SVZ. Since the SGZ cells are not typically glial 
precursors, they may be expected not to respond to signals from myelin disruption and 
oligodendrocyte death.  Perhaps this is why BrdU counts in the SGZ do not recover while the 
SVZ does show some recovery.  
This conclusion that mitotically active cells that are not in the oligodendrocyte lineage 
suffer from cuprizone toxicity also helps to explain the size of the decrease initially seen in 
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the SVZ.  Alvarez-Buylla’s lab showed that only 15% of the cells normally present in the 
SVZ are likely to be glial precursors (Doetsch et al., 1997).  If cuprizone were only toxic to 
these cells, then the change in BrdU+ cell numbers should not be as drastic as 90% of 
control.  However, if cuprizone were toxic to more generic dividing cells, such a large 
decrease would be expected. 
4.4 These Findings Confirm Hypothesized OPC Susceptibility to Cuprizone 
 The hypothesis tested by these experiments was that the oligodendrocyte progenitor 
cells should be susceptible to the effects of cuprizone.  This hypothesis was proposed on the 
basis of the potential mechanism of action of cuprizone and the hypothetical metabolic 
activity of OPCs. Also, if there were anything in the oligodendrocyte lineage that makes them 
susceptible for non-metabolic reasons, then OPCs may share that susceptibility.  The data 
presented here support this hypothesis, suggesting that, in fact, the immature cells of the SVZ 
and SGZ may be more sensitive to cuprizone toxicity than mature oligodendrocytes are. 
4.5 Insights in the Mechanism of Action of Cuprizone 
 The observation that such a large majority of the BrdU+ cells in both the SVZ and 
SGZ responds to cuprizone does support the idea that OPCs are affected by cuprizone, but it 
also suggests that OPCs are not the only cells in these regions that suffer from cuprizone 
toxicity.  There is no evidence here that early OPCs are more sensitive than other dividing cell 
types in the CNS. This suggests that there is not a feature common to the oligodendrocyte 
lineage that makes them susceptible to cuprizone, which leaves the default explanation that the 
effects of cuprizone are due to metabolic effects. 
4.6 Applications of the Cuprizone Model Considering This Result 
 The finding that the dividing cells of the SGZ and SVZ are susceptible to cuprizone is 
not only a novel observation, but it also has significant ramifications for the uses of the 
cuprizone model.  These data may call into question the suitability of cuprizone toxicity as the 
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model of choice for studying remyelination.  Other uses of the cuprizone model may also 
need to be reconsidered in light of these findings. 
 It is known that cells in the SVZ can differentiate into myelinating oligodendrocytes 
(Menn et al., 2006).  Given this, it follows that any toxin that acts on these cells may interfere 
with myelination.  The cuprizone model is widely used to study the processes of 
demyelination and remyelination (Blakemore, 1973a; Koutsoudaki, 2009).  Bearing in mind 
the toxic compound’s effects on immature cells in the SVZ and the potential role of OPCs in 
remyelination, results of these studies may need to be reinterpreted.  Presumably, 
remyelination cannot proceed in the same fashion with these immature cells responding to 
cuprizone as it would were they unaffected as they have been assumed to be.   
 Some studies have used the cuprizone model to investigate the response of OPC 
populations to demyelinating events (Raine et al., 1988; Blakemore and Franklin, 1991; 
Mason et al., 2004).  Therapeutic approaches using OPCs have also been tested in the 
cuprizone model (Blakemore and Irvine, 2008).  Considering the current data, there are 
several reasons that cuprizone may be a poor choice for studies of this nature.  If cuprizone 
affects immature OPCs, as it appears to, then using the model to cause demyelination in 
studies investigating the OPCs themselves may weaken or invalidate the results.  For a study 
of this nature, the OPC response should be exclusively due to demyelination, not to the toxin 
causing the demyelination.  Also, in vitro studies have shown that cuprizone prevents the 
differentiation of adult OPCs (Cammer, 1999).  Therefore, therapeutic studies that use less 
immature OPCs may still have the same problem; the cells respond to the toxin, not just to the 
demyelination.  One may expect that OPCs would have a more robust response to 
demyelination itself than is found in cuprizone studies. Another consideration regarding 
cuprizone and OPC research is the increase in OPC proliferation in the SVZ associated with 
MS in humans. 
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 The evidence presented here needs to be considered when researchers choose the 
most appropriate model system for their work.  Experimental aims that focus on the process 
of remyelination or on OPCs responding to demyelination might exclude cuprizone as an 
option.  However, cuprizone is still a fine choice for demyelination because it is not immune 
mediated and is very consistent.  Also, these results have little impact on studies of axoglial 
interactions and demyelination-induced axon damage.  For many studies, cuprizone could be 
a very good model, but the applicability of the model is narrowed by this observation that 
cuprizone affects CNS cells other than mature oligodendrocytes 
4.7 Conclusion 
 The cuprizone model has been popularly used to study demyelination and 
remyelination for a half-century because it produces consistent results and has been thought 
only to affect myelinating oligodendrocytes, sparing other CNS cell types. However, our 
observations indicate that oligodendrocytes are not the only CNS cells susceptible to the toxic 
effects of cuprizone.  This immunohistochemical study of BrdU incorporation indicates that 
populations of dividing cells in the subventricular and subgranular zones of adult mice are 
very sensitive to the toxin.  These results suggest that cuprizone causes cell death or cell cycle 
perturbation in oligodendrocyte progenitor cells and other proliferative cell types.    
 This novel insight into the cuprizone model could have significant ramifications for its 
applicability to future studies and for the interpretation of prior research.  The results of many 
experiments using this model system may be undermined or invalidated by the direct effects 
of cuprizone on OPCs.  Considering this new finding, future studies concerning OPCs and 
remyelination should weigh alternative models carefully.   
 The current study of the cuprizone model is not able to provide sufficient evidence to 
specifically discriminate between the possible cellular events responsible for the observed 
changes in BrdU+ labeling.  Further pursuit of this question by investigating additional time 
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points, looking for signs of cell death, and attempting to identify the cells that take up BrdU is 
in progress.  Cuprizone can still be an effective model to study various aspects of 
demyelination. Hopefully, this addition to the body of knowledge describing the actions of 
the cuprizone model will help to explain and interpret results obtained using the model and 
further the understanding of demyelination/remyelination processes and the development of 
more effective therapies for myelin disorders like multiple sclerosis.       
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